- Home
- MATH vs ANL Comparison
MATH vs ANL Comparison
Compare MATH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MATH | ANL |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | Hong Kong | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MATH | ANL |
|---|---|---|
| Price | $2.72 | $1.35 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 102.0K | 28.5K |
| Earning Date | 12-05-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.56 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $0.99 | $0.88 |
| 52 Week High | $4.17 | $2.99 |
Technical Indicators
Market Signals| Indicator | MATH | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 51.04 |
| Support Level | $2.84 | $0.88 |
| Resistance Level | $3.04 | $1.59 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 32.26 | 70.48 |
Price Performance
Historical ComparisonAbout MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.